What analyst predict for Brainstorm Cell Therapeutics NASDAQ:BCLI ?

3
342

What analyst predict for Brainstorm Cell Therapeutics NASDAQ:BCLI ?

Brainstorm Cell Therapeutics NASDAQ:BCLI headquartered in New York City, New York, United States is reporting their earnings on 05/14/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.14.

According to stock market daily analyst this is Lower then same time previous year. Brainstorm Cell Therapeutics reported EPS for the same quarter last year was $-0.1.

()
()

Chart

Overview of Brainstorm Cell Therapeutics NASDAQ:BCLI

BrainStorm Cell Therapeutics Inc. is a biotechnology company developing autologous adult stem cell therapies for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Parkinson’s disease (PD)

BCLI
Name
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate

Loews Corporation NYSE:L is reporting this earnings, what to expect.

3 COMMENTS

Comments are closed.